A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.

被引：1
|
作者：
Fujii, Takeo
Masuda, Hiroko
Cheng, Yee Chung
Yang, Fei
Sahin, Aysegul A.
Naoi, Yasuto
Matsunaga, Yuki
Raghavendra, Akshara Singareeka
Sinha, Arup Kumar
Fernandez, Jose R. Espinosa
James, Anjali
Yamagishi, Keisuke
Matsushima, Tomoko
Tripathy, Debu
Tada, Sachiyo
Jackson, Rubie S.
Noguchi, Shinzaburo
Nakamura, Seigo
Acoba, Jared David
Ueno, Naoto T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Med Coll Wisconsin, Menomonee Falls, WI USA
[4] Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan
[5] Showa Univ, Tokyo, Japan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[7] Sysmex Corp, Kobe, Hyogo, Japan
[8] Sysmex Corp, Cent Res Labs, Kobe, Hyogo, Japan
[9] Anne Arundel Med Ctr, Rebecca Fortney Breast Ctr, Annapolis, MD USA
[10] Osaka Univ, Dept Breast & Endocrine Surg, Grad Sch Med, Osaka, Japan
[11] Showa Univ, Sch Med, Div Breast Surg Oncol, Dept Surg, Tokyo, Japan
[12] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA
[13] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
542
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores
    Takeo Fujii
    Hiroko Masuda
    Yee Chung Cheng
    Fei Yang
    Aysegul A. Sahin
    Yasuto Naoi
    Yuki Matsunaga
    Akshara Raghavendra
    Arup Kumar Sinha
    Jose Rodrigo Espinosa Fernandez
    Anjali James
    Keisuke Yamagishi
    Tomoko Matsushima
    Robert Schuetz
    Debu Tripathy
    Sachiyo Tada
    Rubie S. Jackson
    Shinzaburo Noguchi
    Seigo Nakamura
    Jared D. Acoba
    Naoto T. Ueno
    [J]. Breast Cancer Research and Treatment, 2021, 189 : 455 - 461
  • [2] A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores
    Fujii, Takeo
    Masuda, Hiroko
    Cheng, Yee Chung
    Yang, Fei
    Sahin, Aysegul A.
    Naoi, Yasuto
    Matsunaga, Yuki
    Raghavendra, Akshara
    Sinha, Arup Kumar
    Fernandez, Jose Rodrigo Espinosa
    James, Anjali
    Yamagishi, Keisuke
    Matsushima, Tomoko
    Schuetz, Robert
    Tripathy, Debu
    Tada, Sachiyo
    Jackson, Rubie S.
    Noguchi, Shinzaburo
    Nakamura, Seigo
    Acoba, Jared D.
    Ueno, Naoto T.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 455 - 461
  • [3] Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients
    Yasuto Naoi
    Kazuki Kishi
    Ryo Tsunashima
    Kenzo Shimazu
    Atsushi Shimomura
    Naomi Maruyama
    Masafumi Shimoda
    Naofumi Kagara
    Yosuke Baba
    Seung Jin Kim
    Shinzaburo Noguchi
    [J]. Breast Cancer Research and Treatment, 2013, 140 : 299 - 306
  • [4] Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients
    Naoi, Yasuto
    Kishi, Kazuki
    Tsunashima, Ryo
    Shimazu, Kenzo
    Shimomura, Atsushi
    Maruyama, Naomi
    Shimoda, Masafumi
    Kagara, Naofumi
    Baba, Yosuke
    Kim, Seung Jin
    Noguchi, Shinzaburo
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (02) : 299 - 306
  • [5] Validation of the prognosis of patients with ER-positive, HER2-negative and node-negative invasive breast cancer classified as low risk by Curebest™ 95GC Breast in a multi-institutional registry study
    Naoi, Yasuto
    Tsunashima, Ryo
    Shimazu, Kenzo
    Oikawa, Masahiro
    Imanishi, Seiichi
    Koyama, Hiroshi
    Kamada, Yoshihiko
    Ishihara, Kazuhiro
    Suzuki, Masahiko
    Osako, Tomo
    Kinoshita, Takayuki
    Suto, Akihiko
    Nakamura, Seigo
    Tsuda, Hitoshi
    Noguchi, Shinzaburo
    [J]. ONCOLOGY LETTERS, 2023, 25 (05)
  • [6] Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer
    Sestak, Ivana
    Ferree, Sean
    Shemesh, Itay
    Buckingham, Wesley
    Cuzick, Jack
    Dowsett, Mitchell
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [7] Comparison of pathological features of estrogen receptor-positive/HER2-negative early breast cancer in the intermediate-risk group of the 21 gene recurrence score (Oncotype Dx) divided into low and high-risk groups by the 95 gene classifier (Curebest 95GC Breast).
    Kamada, Yoshihiko
    Tsuchiya, Seiko
    Takigami, Naoko
    Tamaki, Kentaro
    Uehara, Kanou
    Tamaki, Nobumitsu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Lee, Su Hyun
    Ha, Seunggyun
    An, Hyun Joon
    Lee, Jae Sung
    Han, Wonshik
    Im, Seock-Ah
    Ryu, Han Suk
    Kim, Won Hwa
    Chang, Jung Min
    Cho, Nariya
    Moon, Woo Kyung
    Cheon, Gi Jeong
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) : 1574 - 1584
  • [9] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Su Hyun Lee
    Seunggyun Ha
    Hyun Joon An
    Jae Sung Lee
    Wonshik Han
    Seock-Ah Im
    Han Suk Ryu
    Won Hwa Kim
    Jung Min Chang
    Nariya Cho
    Woo Kyung Moon
    Gi Jeong Cheon
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1574 - 1584
  • [10] Development of recurrence risk score using 95-gene classifier and its application to formalin-fixed paraffin-embedded tissues in ER-positive, HER2-negative and node-negative breast cancer
    Naoi, Yasuto
    Saito, Yuria
    Kishi, Kazuki
    Shimoda, Masafumi
    Kagara, Naofumi
    Miyake, Tomohiro
    Tanei, Tomonori
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    [J]. ONCOLOGY REPORTS, 2019, 42 (06) : 2680 - 2685
12345